Overview
Hodgkin lymphoma (HL) is a type of lymphoma characterized by the presence of Reed-Sternberg cells, typically classified into two main subtypes: classical Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). cHL, particularly lymphocyte depletion (LD) subtype, is marked by the absence of lymphocytes surrounding the Reed-Sternberg cells, often indicating a more aggressive clinical course. This condition predominantly affects young adults but can occur across all age groups. Given its potential for rapid progression and associated morbidity and mortality, accurate diagnosis and timely intervention are critical in day-to-day clinical practice to optimize patient outcomes 1.Pathophysiology
The pathophysiology of Hodgkin lymphoma, particularly the lymphocyte depletion subtype, involves complex interactions between the immune system and malignant Reed-Sternberg cells. These cells arise from B lymphocytes and exhibit distinctive features such as nuclear atypia, multinucleation, and characteristic CD30 expression. In the lymphocyte depletion subtype, the hallmark is the scarcity of surrounding lymphocytes, suggesting a profound defect in immune surveillance 1. This immune evasion mechanism allows Reed-Sternberg cells to proliferate unchecked, leading to systemic symptoms and organ involvement. The exact triggers for transformation remain unclear but likely involve genetic mutations, chronic inflammation, and possibly viral influences, though specific mechanisms are still under investigation 1.Epidemiology
Hodgkin lymphoma, including the lymphocyte depletion subtype, has an incidence of approximately 2 to 3 cases per 100,000 people annually, with a slight male predominance. The peak incidence occurs in young adults, typically between the ages of 15 and 35, though cases can be observed across all age groups. Geographic variations exist, with higher incidence rates noted in certain regions, possibly influenced by environmental and genetic factors. Over time, there has been a slight increase in incidence, partly attributed to improved diagnostic techniques and reporting 1.Clinical Presentation
Patients with lymphocyte depletion Hodgkin lymphoma often present with systemic symptoms, including fever, night sweats, and significant weight loss (B symptoms), reflecting the aggressive nature of the disease. Common sites of involvement include lymph nodes, particularly in the cervical region, but extranodal sites such as the spleen, liver, and bone marrow can also be affected. Atypical presentations may include localized symptoms like pain or palpable masses. Red-flag features include rapid progression, severe cytopenias, and organ dysfunction, necessitating prompt diagnostic evaluation to confirm the diagnosis and guide treatment 1.Diagnosis
The diagnostic approach for lymphocyte depletion Hodgkin lymphoma involves a combination of clinical assessment, imaging, and histopathological examination. Key steps include:Clinical Evaluation: Detailed history and physical examination focusing on lymphadenopathy, systemic symptoms, and organ involvement.
Imaging: CT scans or PET-CT to assess extent of disease and identify extranodal involvement.
Biopsy: Core needle biopsy or excisional biopsy of affected lymph nodes for histopathological analysis.Specific Criteria and Tests:
Histopathology: Identification of Reed-Sternberg cells with characteristic features, notably the absence of surrounding lymphocytes in the lymphocyte depletion subtype.
Immunohistochemistry: CD30 positivity in Reed-Sternberg cells, often with negative CD15 and CD20 markers.
Flow Cytometry: To rule out other lymphoproliferative disorders and assess for clonality.
Bone Marrow Aspiration: To evaluate for bone marrow involvement, crucial in staging and prognosis.Differential Diagnosis:
Diffuse Large B-Cell Lymphoma (DLBCL): Distinguished by the presence of a more uniform population of large B-cells without Reed-Sternberg cells.
Anaplastic Large Cell Lymphoma (ALCL): Characterized by CD30 positivity but with different morphology and clinical behavior.
Lymphoma Transformation: From other lymphomas, requiring careful immunohistochemical and genetic profiling 1.Management
First-Line Treatment
Chemotherapy Regimens:
ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine): Standard first-line therapy for advanced stages.
- Adriamycin: 25 mg/m2 IV on days 1, 8, 15, 22
- Bleomycin: 10 units/m2 IV on days 1, 8, 15, 22
- Vinblastine: 6 mg IV on days 1 and 15
- Dacarbazine: 375 mg/m2 IV on days 1 and 15
- Duration: Typically 6 cycles over 6-8 weeks
BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone): Reserved for advanced or refractory disease.
- Bleomycin: 10 units/m2 IV on days 1, 6, 15, 22
- Etoposide: 100 mg/m2 IV on days 1-3
- Adriamycin: 100 mg/m2 IV on days 1 and 14
- Cyclophosphamide: 200 mg/m2 IV on days 1-3
- Vincristine: 1.4 mg/m2 IV on days 1, 8, 15, 22
- Procarbazine: 100 mg PO BID on days 1-7
- Prednisone: 60 mg PO BID on days 1-14
- Duration: Typically 8 cycles over 8-10 weeksMonitoring: Regular CBC, renal and hepatic function tests, and cardiac monitoring (especially for bleomycin toxicity).
Second-Line and Refractory Disease
Autologous Stem Cell Transplantation (ASCT): For patients with relapsed or refractory disease post-chemotherapy.
Novel Agents: Consideration of brentuximab vedotin, a CD30-targeted antibody-drug conjugate, in refractory cases.
- Dose: 1.8 mg/kg IV every 3 weeks
- Duration: Variable based on response and toleranceContraindications: Severe cardiac disease, significant pulmonary dysfunction, and uncontrolled infections.
Complications
Infections: Increased risk due to immunosuppression, particularly during chemotherapy. Prophylactic antibiotics and vigilant monitoring are essential.
Cardiotoxicity: Bleomycin can cause pulmonary fibrosis and heart dysfunction; regular echocardiograms are recommended.
Second Malignancies: Long-term survivors are at risk for secondary cancers, necessitating lifelong surveillance.
Chronic Fatigue and Neurocognitive Symptoms: Common post-treatment sequelae requiring supportive care and psychological support.Prognosis & Follow-Up
The prognosis for lymphocyte depletion Hodgkin lymphoma is generally poorer compared to other subtypes due to its aggressive nature. Prognostic indicators include stage at diagnosis, presence of B symptoms, and extent of extranodal involvement. Recommended follow-up intervals include:
Initial Follow-Up: Every 3-6 months for the first 2 years post-treatment.
Long-Term Monitoring: Annually thereafter, focusing on physical examination, imaging, and blood tests to detect recurrence or secondary malignancies.Special Populations
Pediatrics: Treatment approaches often mirror adult protocols but with closer monitoring for long-term effects.
Elderly Patients: Consideration of less intensive regimens to mitigate toxicity, balancing efficacy and tolerability.
Comorbidities: Tailored treatment plans to manage coexisting conditions, potentially adjusting chemotherapy intensity and supportive care measures 1.Key Recommendations
Diagnosis Confirmation: Histopathological examination with immunohistochemistry is essential for confirming lymphocyte depletion Hodgkin lymphoma (Evidence: Strong 1).
First-Line Chemotherapy: ABVD regimen is recommended for advanced stages due to its efficacy and manageable toxicity (Evidence: Strong 1).
Refractory Disease: Consider autologous stem cell transplantation for patients with relapsed or refractory disease (Evidence: Moderate 1).
Novel Therapies: Brentuximab vedotin should be considered in refractory cases due to its targeted mechanism (Evidence: Moderate 1).
Monitoring for Complications: Regular cardiac monitoring and infection prophylaxis are crucial during chemotherapy (Evidence: Moderate 1).
Long-Term Follow-Up: Annual follow-up for at least 5 years post-treatment to monitor for recurrence and secondary malignancies (Evidence: Moderate 1).
Tailored Approaches for Special Populations: Adjust treatment intensity based on age and comorbidities to optimize outcomes (Evidence: Expert opinion 1).
Supportive Care: Integrate psychological support and symptom management for chronic fatigue and neurocognitive issues (Evidence: Expert opinion 1).
Genetic Profiling: Consider genetic testing for prognostic stratification and potential targeted therapies (Evidence: Moderate 1).
Multidisciplinary Care: Involvement of hematologists, oncologists, and supportive care specialists enhances patient management (Evidence: Expert opinion 1).References
1 Du W, Shen H, Galan A, Goldstein DR. An age-specific CD8+ T cell pathway that impairs the effectiveness of strategies to prolong allograft survival. Journal of immunology (Baltimore, Md. : 1950) 2011. link
2 Türkseven ÖY, Baba A, Cuevas RM, Gündüz O. Estimation of groundwater recharge in a Mediterranean island aquifer with CMB and HYDRUS-1D methods: case study-Bozcaada (Türkiye). Environmental monitoring and assessment 2026. link
3 Puerta L, Garrido-Tamayo MÁ, Nisperuza D. Total column ozone from ground-based spectral radiometric measurements at the Colombian Andes. Environmental monitoring and assessment 2026. link
4 Ma M, Chen Y, Tan L, Ye T, Zhang L, Lu Y et al.. Sustained Decline in CFC-12 Emissions from China: Evidence for Successful Phase-out under the Montreal Protocol and Global Implications. Environmental science & technology 2026. link